

Accepted Manuscript

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

Lucio Boglione, MD Amedeo De Nicolò, Chiara Simona Cardellino, Tina Ruggiero, Valeria Ghisetti, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio

PII: S1198-743X(14)00025-1

DOI: [10.1016/j.cmi.2014.07.009](https://doi.org/10.1016/j.cmi.2014.07.009)

Reference: CMI 24

To appear in: *Clinical Microbiology and Infection*


Received Date: 22 April 2014

Revised Date: 17 July 2014

Accepted Date: 20 July 2014

Please cite this article as: Boglione L, De Nicolò A, Cardellino CS, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D'Avolio A, Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, *Clinical Microbiology and Infection* (2014), doi: 10.1016/j.cmi.2014.07.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TITLE: Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.

Authors: Lucio Boglione*, Amedeo De Nicolò*, Chiara Simona Cardellino, Tina Ruggiero, Valeria Ghisetti, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio,

Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

*both Authors contributed equally to this paper

Number of Figures and Tables: 1 and 1

Abbreviations: hepatitis C virus, HCV; chronic hepatitis C, CHC; pegylated interferon, PEG-IFN; ribavirin, RBV; telaprevir, TVR; boceprevir, BOC; boceprevir-S isomer, BOC-S; protease inhibitors, PIs; sustained virological response, SVR; breakthrough, BT; direct-acting antiviral agents, DAAs; non-structural, NS; resistance associated amino acid variants, RAVs; ultra-performance liquid chromatography with Tandem Mass detector, UPLC-MS/MS; high-performance liquid chromatography with UV detector, HPLC-UV; interleukin 28B, IL28B; null-responder, NR; partial responder, PR; relapse, REL; receiver-operating characteristic, ROC; area under the curve, AUC; three times a day, TID; pharmacokinetics, PK; therapeutic drug monitoring, TDM; inter quartile range, IQR;

Word count: (excluding references, tables and abstract): 993

Short title: boceprevir plasma concentration and virological breakthrough

Corresponding Author: Lucio Boglione, (MD); Tel. +39.011.4393802, Fax:

+39.011.4393975; e-mail: lucio.boglione@unito.it

Funding: none

Competing interests: none declared

Ethical approved: not required

Download English Version:

<https://daneshyari.com/en/article/6129754>

Download Persian Version:

<https://daneshyari.com/article/6129754>

[Daneshyari.com](https://daneshyari.com)